PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

To Develop and Implement The Scope of Medical Care for Homologous Recombination Deficient Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer of the III-IV Stages Using Maintenance Therapy With PARP Inhibitor Combined With Angiogenesis Inhibitor.

This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

Inclusion Criteria:

• Age ≥18-≤75 years.
• Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
• Presence of homologous recombination deficiency (HRD).
• No contraindications to chemotherapy, or bevacizumab.
• Signed informed consent to participate in the study.

Exclusion Criteria:

• Presence of another active malignant invasive neoplasm.
• Pregnancy or lactation period.
• Disease progression during treatment.